240 related articles for article (PubMed ID: 29609752)
1. Statin Intolerance: Some Practical Hints.
Banach M; Mikhailidis DP
Cardiol Clin; 2018 May; 36(2):225-231. PubMed ID: 29609752
[TBL] [Abstract][Full Text] [Related]
2. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
3. Statin Intolerance: the Clinician's Perspective.
Stulc T; Ceška R; Gotto AM
Curr Atheroscler Rep; 2015 Dec; 17(12):69. PubMed ID: 26490078
[TBL] [Abstract][Full Text] [Related]
4. Resistance and intolerance to statins.
Reiner Z
Nutr Metab Cardiovasc Dis; 2014 Oct; 24(10):1057-66. PubMed ID: 24996502
[TBL] [Abstract][Full Text] [Related]
5. Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement.
Banach M; Stulc T; Dent R; Toth PP
Int J Cardiol; 2016 Dec; 225():184-196. PubMed ID: 27728862
[TBL] [Abstract][Full Text] [Related]
6. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.
Nicholls S; Lincoff AM; Bays HE; Cho L; Grobbee DE; Kastelein JJ; Libby P; Moriarty PM; Plutzky J; Ray KK; Thompson PD; Sasiela W; Mason D; McCluskey J; Davey D; Wolski K; Nissen SE
Am Heart J; 2021 May; 235():104-112. PubMed ID: 33470195
[TBL] [Abstract][Full Text] [Related]
8. Strategies to overcome statin intolerance.
Agouridis AP; Nair DR; Mikhailidis DP
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):851-5. PubMed ID: 25786568
[TBL] [Abstract][Full Text] [Related]
9. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
Koskinas K; Wilhelm M; Windecker S
Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448
[TBL] [Abstract][Full Text] [Related]
10. Expert opinion: the therapeutic challenges faced by statin intolerance.
Patel J; Martin SS; Banach M
Expert Opin Pharmacother; 2016 Aug; 17(11):1497-507. PubMed ID: 27254275
[TBL] [Abstract][Full Text] [Related]
11. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
12. An assessment by the Statin Intolerance Panel: 2014 update.
Guyton JR; Bays HE; Grundy SM; Jacobson TA; The National Lipid Association Statin Intolerance Panel
J Clin Lipidol; 2014; 8(3 Suppl):S72-81. PubMed ID: 24793444
[TBL] [Abstract][Full Text] [Related]
13. [Practical approach to statin intolerance].
Štulc T; Beránková Š; Češka R
Vnitr Lek; 2015 Nov; 61(11):936-41. PubMed ID: 26652780
[TBL] [Abstract][Full Text] [Related]
14. [Statin intolerance].
Graversen CB; Larsen ML; Schmidt EB
Ugeskr Laeger; 2015 Aug; 177(36):. PubMed ID: 26324293
[TBL] [Abstract][Full Text] [Related]
15. Statin tolerability: In defence of placebo-controlled trials.
Tobert JA; Newman CB
Eur J Prev Cardiol; 2016 May; 23(8):891-6. PubMed ID: 26318980
[TBL] [Abstract][Full Text] [Related]
16. Management of Statin Intolerance in 2018: Still More Questions Than Answers.
Toth PP; Patti AM; Giglio RV; Nikolic D; Castellino G; Rizzo M; Banach M
Am J Cardiovasc Drugs; 2018 Jun; 18(3):157-173. PubMed ID: 29318532
[TBL] [Abstract][Full Text] [Related]
17. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
Stroes E; Colquhoun D; Sullivan D; Civeira F; Rosenson RS; Watts GF; Bruckert E; Cho L; Dent R; Knusel B; Xue A; Scott R; Wasserman SM; Rocco M;
J Am Coll Cardiol; 2014 Jun; 63(23):2541-2548. PubMed ID: 24694531
[TBL] [Abstract][Full Text] [Related]
18. [Up to date lipid lowering treatment].
Paragh G; Karádi I
Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
[TBL] [Abstract][Full Text] [Related]
19. Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association.
Cohen JD; Cziraky MJ; Jacobson TA; Maki KC; Karalis DG
J Clin Lipidol; 2017; 11(4):891-900. PubMed ID: 28550993
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
